MetrioPharm AG Investor Relations News
Patents: Developments in all key markets
MetrioPharm AG was able to make further progress with regard to the patent protection of MP1032 in the first months of 2014.
MP1032 Milestones - on the route to a new drug
The most important outcome was MP1032’s superior safety profi le as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year.